Femasys Inc (FEMY)

NASD · Healthcare · Medical Instruments & Supplies · USA

Femasys Inc is a micro cap company (market value under $300 million) in the Medical Instruments & Supplies industry.

Femasys Inc is a biomedical manufacturer developing patent-protected therapeutic and diagnostic products for women's health. Its portfolio includes FemaSeed for intratubal insemination to treat infertility, FemVue and FemChec for fallopian tube assessment via ultrasound, FemCerv for cervical cancer diagnosis, and FemBloc for non-surgical permanent birth control. Products are cleared or approved in the U.S. and various international markets.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Femasys Inc stock.

Our verdict on FEMY

Overvalued: intrinsic value $0.18 per share, market price $1.12, margin of safety -505.7% (as of 2026-11-17).

Its liquidation floor, current assets minus every liability, values the shares at $0.18; the price of $1.12 is 506% above that value.

ETFs with the most weight in FEMY

More on FEMY

Browse

Peers in Medical Instruments & Supplies

All 52 Medical Instruments & Supplies stocks

Cheaper than FEMY in Medical Instruments & Supplies

21 more in this industry show a wider margin of safety.

Is FEMY undervalued or overvalued?

FEMY is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $0.18; the price of $1.12 is 506% above that value.

What is the intrinsic value of FEMY?

$0.18 per share (as of the 2026-11-17 close), against a market price of $1.12. That is a margin of safety of -505.7%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.